SWOG 9717:EVALUATION OF INTRAVENOUSLY ADMINISTERED TIRAPAZAMINE + CIS

本研究的目的是确定替拉明和顺铂治疗晚期宫颈癌的效果。目前，子宫颈癌是美国妇女第四大最常见的恶性肿瘤，也是导致妇科恶性肿瘤死亡的第二大原因。宫颈癌的治疗结果是顽固性或复发后的主要治疗仍然令人失望。因此，研究正在进行中，以确定更有效的化疗方案，为这种疾病。这种癌症是一种相对耐化疗的肿瘤，其疗效往往因先前放疗的并发症而进一步降低。此外，体积庞大的肿瘤块和血液供应不足往往导致大部分肿瘤细胞处于缺氧环境，这限制了大多数标准化疗药物的疗效。替拉帕嗪是一种实验性化疗药物，专门开发用于增强抗缺氧细胞的活性。本研究旨在研究复发或难治性宫颈癌患者每21天使用顺铂和替拉帕嗪联合治疗的疗效和毒性。

The purpose of this study is to determine how effective treatment with tirapamine and cisplatin is in treating advanced cervical cancer. At present, cervical cancer is the fourth most common malignancy in American women, and the second leading cause of death from gynecologic malignancy. Therapeutic outcome for cervical carcinoma which is refractory or recurrent following primary therapy remains disappointing. Thus, research is ongoing to identify more effective chemotherapeutic regimens for this disease. This cancer is a relatively chemoresistant tumor, and the efficaicy is often further diminished by complications of prior radiation therapy. Additionally, the contribution of bulky tumor masses and poor blood supply often results in a hypoxic environment for a large percentage of tumor cells which limits the efficacy of most standard chemotherapeutic agents. Tirapazamine is an investigational chemotherapeutic agent which was specifically developed to have increased activity against hypoxic cells. The present study has been designed to study the efficacy and toxicities associated with a combination of cisplatin plus tirapazamine administered every 21 days in patients with recurrent or refractory cervix cancer.